RTTNews | Oct 8, 2020 10:02AM EDT

10:02 Thursday, October 8, 2020 (RTTNews.com) - Cytokinetics, Inc. (CYTK) shares are sliding more than 42 percent on Thursday morning trade.

Cytokinetics, Amgen, and Servier alliance's phase 3 pivotal clinical trial - Galactic-HF of omecamtive mecarbil in patients with heart failure failed to meet the secondary endpoint of reduction in cardiovascular death. CYTK said the trial met its primary composite endpoint.

Currently, the shares are at $16.01, down 42.11 percent from its previous close of $27.66.

Read the original article on RTTNews ( https://www.rttnews.com/3134882/stock-alert-cytokinetics-down-42.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved